Skip to main content

Advertisement

Table 1 Clinical characteristics for each group study

From: No detectable differential microRNA expression between non-atherosclerotic arteries of type 2 diabetic patients (treated or untreated with metformin) and non-diabetic patients

  Study group 1 (explorative analysis)
T2DM n = 18 Non-DM n = 30 P T2DM (− Met) n = 8 Non-DM n = 30 P T2DM (+ Met) n = 10 T2DM (− Met) n = 8 P
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Age at surgery, years 66.61 ± 7.51 63.60 ± 8.98 0.219 67.13 ± 8.63 63.60 ± 8.98 0.330 66.20 ± 6.94 67.13 ± 8.63 0.809
HbA1c, % 6.94 ± 1.21 5.74 ± 0.38 0.002 7.37 ± 1.52 5.74 ± 0.38 0.029 6.56 ± 0.76 7.37 ± 1.52 0.236
HbA1c, mmol/mol 52.28 ± 13.07 39.21 ± 4.08 0.002 56.93 ± 16.41 39.21 ± 4.08 0.029 48.21 ± 8.36 56.93 ± 16.41 0.238
Cholesterol, mmol/L 4.19 ± 1.11 4.45 ± 1.16 0.486 4.27 ± 1.16 4.45 ± 1.16 0.721 4.11 ± 1.14 4.27 ± 1.16 0.803
LDL, mmol/L 2.31 ± 0.70 2.61 ± 1.01 0.267 2.41 ± 0.76 2.61 ± 1.01 0.571 2.21 ± 0.68 2.41 ± 0.76 0.614
HDL, mmol/L 1.16 ± 0.38 1.21 ± 0.33 0.684 1.01 ± 0.24 1.21 ± 0.33 0.101 1.30 ± 0.46 1.01 ± 0.24 0.168
Triglycerides, mmol/L 1.88 ± 1.21 1.45 ± 0.63 0.210 2.23 ± 1.54 1.45 ± 0.63 0.234 1.58 ± 0.81 2.23 ± 1.54 0.344
Creatinine, µmol/L 83.72 ± 15.42 85.70 ± 13.14 0.653 76.88 ± 11.22 85.70 ± 13.14 0.080 89.20 ± 16.62 76.88 ± 11.22 0.080
BMI, kg/m2 29.98 ± 3.06 27.26 ± 3.77 0.010 29.24 ± 2.57 27.26 ± 3.77 0.104 30.57 ± 3.42 29.24 ± 2.57 0.360
SBP, mm Hg 134.22 ± 19.47 138.42 ± 22.13 0.510 141.38 ± 22.36 138.42 ± 22.13 0.749 128.50 ± 15.66 141.38 ± 22.36 0.192
DBP, mm Hg 75.06 ± 11.61 77.70 ± 12.78 0.476 80.00 ± 14.63 77.70 ± 12.78 0.697 71.10 ± 7.02 80.00 ± 14.63 0.146
Male sex, % 100 100 100 100 100 100
Statins, n 18 30 8 30 10 8
Antihypertensives, n 17 26 0.637 7 26 1.000 10 7 0.444
Insulins, n 6 0 0.002 4 0 < 0.001 2 4 0.321
Oral antidiabetic agents, n 12 0 < 0.001 2 0 0.040 10 2 0.002
  1. For each study group three comparisons of clinical data are made: T2DM vs. non-DM patients; non-metformin-treated T2DM (− Met) vs. non-DM patients; and non-metformin-treated T2DM (− Met) vs. metformin-treated T2DM patients (+ Met). Results are shown as mean ± SD, percentage (%) or number (n) as indicated
  2. In study group 1, one slide cracked during the hybridization process. Since no miRNA expression data is available for this sample, the accompanying patient data is not included in the table
  3. HbA1c glycated hemoglobin, LDL low-density lipoprotein, HDL high-density lipoprotein, BMI Body-mass index, SBP systolic blood pressure, DBP diastolic blood pressure
  Study group 2 (targeted analysis)
T2DM n = 26 Non-DM n = 26 P T2DM (− Met) n = 11 Non-DM n = 26 P T2DM (+ Met) n = 15 T2DM (− Met) n = 11 P
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Age at surgery, years 67.84 ± 4.83 68.99 ± 5.24 0.410 67.35 ± 4.21 68.99 ± 5.24 0.367 68.25 ± 5.35 67.35 ± 4.21 0.670
HbA1c, % 7.11 ± 1.11 5.60 ± 0.37 < 0.001 7.41 ± 1.39 5.60 ± 0.37 < 0.001 6.84 ± 0.75 7.41 ± 1.39 0.231
HbA1c, mmol/mol 54.24 ± 12.17 37.71 ± 4.03 < 0.001 57.48 ± 15.19 37.71 ± 4.03 < 0.001 51.28 ± 8.16 57.48 ± 15.19 0.230
Cholesterol, mmol/L 3.76 ± 1.04 4.20 ± 1.26 0.230 4.00 ± 1.32 4.20 ± 1.26 0.692 3.55 ± 0.68 4.00 ± 1.32 0.329
LDL, mmol/L 1.85 ± 0.69 2.33 ± 0.90 0.058 2.07 ± 0.87 2.33 ± 0.90 0.447 1.65 ± 0.42 2.07 ± 0.87 0.174
HDL, mmol/L 1.13 ± 0.24 1.41 ± 0.51 0.030 1.14 ± 0.25 1.41 ± 0.51 0.129 1.12 ± 0.25 1.14 ± 0.25 0.851
Triglycerides, mmol/L 1.90 ± 0.89 1.21 ± 0.35 0.002 1.89 ± 1.03 1.21 ± 0.35 0.011 1.91 ± 0.79 1.89 ± 1.03 0.960
Creatinine, µmol/L 96.12 ± 29.47 86.40 ± 16.93 0.160 95.64 ± 32.61 86.40 ± 16.93 0.269 96.47 ± 28.12 95.64 ± 32.61 0.945
BMI, kg/m2 28.66 ± 3.95 27.13 ± 3.69 0.150 27.21 ± 3.41 27.13 ± 3.69 0.949 29.73 ± 4.08 27.21 ± 3.41 0.110
SBP, mm Hg 141.12 ± 18.64 139.92 ± 19.79 0.820 138.82 ± 10.59 139.92 ± 19.79 0.863 142.80 ± 23.09 138.82 ± 10.59 0.601
DBP, mm Hg 74.92 ± 10.42 77.73 ± 10.71 0.340 75.73 ± 12.28 77.73 ± 10.71 0.621 74.33 ± 9.24 75.73 ± 12.28 0.744
Male sex, % 85 85 82 85 87 82
Statins, n 26 26 11 26 15 11
Antihypertensives, n 21 13 0.040 8 13 0.285 13 8 0.620
Insulins, n 6 0 0.023 3 0 0.021 3 3 0.218
Oral antidiabetic agents, n 19 0 < 0.001 4 0 0.005 15 4 < 0.001
  1. For each study group three comparisons of clinical data are made: T2DM vs. non-DM patients; non-metformin-treated T2DM (− Met) vs. non-DM patients; and non-metformin-treated T2DM (− Met) vs. metformin-treated T2DM patients (+ Met). Results are shown as mean ± SD, percentage (%) or number (n) as indicated
  2. In study group 1, one slide cracked during the hybridization process. Since no miRNA expression data is available for this sample, the accompanying patient data is not included in the table
  3. HbA1c glycated hemoglobin, LDL low-density lipoprotein, HDL high-density lipoprotein, BMI Body-mass index, SBP systolic blood pressure, DBP diastolic blood pressure